Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pharma s subsidiary acrotech biopharma
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Pharma S Subsidiary Acrotech Biopharma Articles & Analysis

27 news found

Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide. Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “Whether customers are trying to develop a ...

ByProtheragen-ING


Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy

Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy

Watertown, MA — October 24, 2024 — Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical ...

ByBiopharma PEG Scientific Inc


PDA Announces the Jette Christensen Early Career Professional Grant in Memory of Past PDA Chair

PDA Announces the Jette Christensen Early Career Professional Grant in Memory of Past PDA Chair

PDA today announced the establishment of the Jette Christensen Early Career Professional Grant in memory of the Immediate-Past Chair of the PDA Board of Directors, who passed away on October 24 after a long battle with cancer. As a PDA member, Board Member, and PDA Chair, Jette’s dedication to PDA’s mission of advancing pharmaceutical/biopharmaceutical manufacturing science and ...

ByParenteral Drug Association (PDA)


VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry

VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry

Frost & Sullivan recently assessed the artificial intelligence (AI)-enabled preclinical development industry, and, based on its analysis results, recognizes VeriSIM Life with the 2022 North America Competitive Strategy Leadership Award. The company's core mission is to increase human life expectancy through artificial intelligence-driven biosystem simulations and to personalize patient ...

ByVeriSIM Life


Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer Company Believes LifeSci Proxy ...

ByCervoMed


Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the “Board”) has authorized a thorough review and evaluation of a range of potential ...

ByCervoMed


SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University

SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University

SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. Lung cancer is the leading cause of cancer death accounting for almost one quarter of annual ...

BySEngine Precision Medicine


Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients Company to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected ...

ByCervoMed


Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-tolerated by all subjects with no serious adverse events reported Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) ...

ByCervoMed


EsoCap Announces Publication “Development of a HotMelt Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns”

EsoCap Announces Publication “Development of a HotMelt Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns”

EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...

ByEsoCap AG


Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Diffusion Pharmaceuticals Inc.(NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright ...

ByCervoMed


Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three ...

ByCervoMed


End-to-End Multi-Attribute Method Solution Accelerates Biotherapeutic Development and Manufacturing

End-to-End Multi-Attribute Method Solution Accelerates Biotherapeutic Development and Manufacturing

ASMS 2021 – Biopharmaceutical laboratories working across R&D, manufacturing and quality control (QC) environments can now streamline biopharmaceutical characterization, process monitoring and release testing using a new seamless, built-for-purpose multi-attribute method (MAM) workflow. The Thermo Scientific MAM 2.0 workflow is a culmination of collaborations and conversations with ...

ByThermo Fisher Scientific


Esocap announces publication of “Functionality and Acceptance of the EsoCap System - a Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study“

Esocap announces publication of “Functionality and Acceptance of the EsoCap System - a Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study“

EsoCap has announced that scientists from the University of Greifswald have published exciting data demonstrating the high level of acceptance of its novel drug delivery technology enabling targeted and long-lasting local therapy of the esophagus (Rosenbaum et al., Pharmaceutics 2021, 13, 828). In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit ...

ByEsoCap AG


Thermo Fisher Scientific Announces Agreement with Advanced Electrophoresis Solutions Ltd to Accelerate Therapeutic Development through Cutting-Edge Protein Analysis

Thermo Fisher Scientific Announces Agreement with Advanced Electrophoresis Solutions Ltd to Accelerate Therapeutic Development through Cutting-Edge Protein Analysis

Thermo Fisher Scientific, the world leader in serving science, and Advanced Electrophoresis Solutions Ltd (AES), specialists in protein imaging technologies, today announced an agreement to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization. Together, the companies will promote Thermo ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


MerLion Pharmaceuticals Completes Growth Financing Round

MerLion Pharmaceuticals Completes Growth Financing Round

MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors. The funds raised will primarily be used to finance the production and market launch of ...

ByMerLion Pharmaceuticals GmbH


Thermo Fisher Scientific Recognized with Six CMO Leadership Awards

Thermo Fisher Scientific Recognized with Six CMO Leadership Awards

Thermo Fisher Scientific, the world leader in serving science, today announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. Thermo Fisher won across all six categories, including: Capabilities, Compatibility, Expertise, ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash. Novasep's viral ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path

Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path

4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company’s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare. ...

By4D Path Inc.


4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images

4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images

4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT, Harvard Medical School and the University of Cambridge, has unveiled a faster, more efficient approach to cancer diagnosis and biomarker profiling with better accuracy that accelerates and democratizes precision medicine for optimized patient care and ...

By4D Path Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT